Literature DB >> 11153541

A proposed pathological model in the hippocampus of subjects with schizophrenia.

E Scarr1, D L Copolov, B Dean.   

Abstract

1. The hippocampal formation plays an important role in the normal functioning of the brain, being implicated in cognition and sensory gating, both of which are affected in schizophrenia. The hippocampal formation receives information from the association cortices, which is processed by glutamatergic transmission within the hippocampus. Dopamine, noradrenaline, 5-hydroxytryptamine (5-HT), acetylcholine and GABA, all of which have been proposed to play a role in the neurobiology of schizophrenia, can affect this transmission. 2. The advent of the 'atypical' antipsychotics, with their broad pharmacological spectra and improved therapeutic outcome, has revitalized research into neurotransmitter dysfunction other than that of dopamine. In particular, there has been interest in the serotonergic and cholinergic systems within the hippocampal formation because these are two of the transmitter systems targeted by clozapine and olanzapine. 3. From the study of these systems, using tissue obtained postmortem from subjects with schizophrenia, we propose that there is a hyperserotonergic state in the hippocampal formation of some subjects with schizophrenia caused by a conformational change in the 5-HT transporter. The model we propose allows us to construct further studies that will test the consequences of such a hyperserotonergic state in the hippocampal formation. This model has the potential to open new avenues in schizophrenia research.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11153541     DOI: 10.1046/j.1440-1681.2001.03400.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  5 in total

Review 1.  Insights and treatment options for psychiatric disorders guided by functional MRI.

Authors:  Tonmoy Sharma
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

2.  Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia.

Authors:  Tonmoy Sharma; Catherine Hughes; William Soni; Veena Kumari
Journal:  Psychopharmacology (Berl)       Date:  2003-07-04       Impact factor: 4.530

3.  Deletion of PLCB1 gene in schizophrenia-affected patients.

Authors:  Vincenza Rita Lo Vasco; Giuseppina Cardinale; Patrizia Polonia
Journal:  J Cell Mol Med       Date:  2012-04       Impact factor: 5.310

4.  Repeated Exposure to the "Spice" Cannabinoid JWH-018 Induces Tolerance and Enhances Responsiveness to 5-HT1A Receptor Stimulation in Male Rats.

Authors:  Joshua S Elmore; Michael H Baumann
Journal:  Front Psychiatry       Date:  2018-02-27       Impact factor: 4.157

Review 5.  Phospholipase C-β1 Hypofunction in the Pathogenesis of Schizophrenia.

Authors:  Seong-Wook Kim; Taesup Cho; Sukchan Lee
Journal:  Front Psychiatry       Date:  2015-11-17       Impact factor: 4.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.